While tau has been known to be involved in AD for many years, recently researchers have begun to view it as a critical mediator of toxicity in disease, setting aside the old paradigm in which extracellular Aβ plaques were considered the most important therapeutic target. This evidence concerns the gene MAPT and Alzheimer disease.